Top

The Journal of Headache and Pain

Published in:

Open Access 01-12-2015 | Research article

Positive effects of the progestin desogestrel 75 μg on migraine frequency and use of acute medication are sustained over a treatment period of 180 days

Authors: Gabriele S Merki-Feld, Bruno Imthurn, Ronald Langner, Burkhardt Seifert, Andreas R Gantenbein

Published in: The Journal of Headache and Pain | Issue 1/2015

Abstract

Background

Premenopausal migraines frequently are associated with fluctuations of estrogen levels. Both, migraine and combined hormonal contraceptives (CHC) increase the risk of vascular events. Therefore progestagen-only contraceptives (POC) are a safer alternative. A previous short-term study demonstrated a positive impact of the oral POC desogestrel on migraine frequency. To study the effect of the POC desogestrel 75 μg on migraine frequency, intensity, use of acute medication and quality of life in a clinical setting over the period of 180 days.

Methods

Patients’ charts were screened for women with migraine, who had decided to use desogestrel for contraception. Charts were included, if routinely conducted headache diaries were complete for 90 days before treatment (baseline) and over a treatment period of 180 days. We also report about starters who stopped treatment early, because of adverse events. Baseline data (day 1–90 before treatment) were compared with first and second treatment period (treatment days 1–90 and days 91–180). Quality of life was evaluated using MIDAS questionnaires.

Results

Days with migraine (5.8 vs 3.6), with any kind of headache (9.4 vs 6.6), headache intensity (15.7 vs 10.7), days with severe headache (5.4 vs 2.4) and use of triptans (12.3 vs7.8) were significantly reduced after 180 days. MIDAS score and grade improved significantly.

Conclusion

Contraception with desogestrel 75 μg resulted in a significantly improved quality of life and a reduction of migraine days over the observation period of 180 days. A clinically meaningful 30% reduction in pain was observed in 25/42 (60%) participants. For counselling reasons it is of importance, that the major reduction in migraine frequency occured during the initial 90 days, however further improvement occurs with longer duration of use. Prospective studies are needed to confirm these results.

Aegidius K, Zwart JA, Hagen K, Schei B, Stovner LJ (2006) Oral contraceptives and increased headache prevalence: the Head-HUNT Study. Neurology 66(3):349–353CrossRefPubMed

Allais G, Gabellari IC, Airola G, Borgogno P, Schiapparelli P, Benedetto C (2009) Headache induced by the use of combined oral contraceptives. Neurol Sci 30(Suppl 1):S15–S17CrossRefPubMed

Teepker M, Peters M, Kundermann B, Vedder H, Schepelmann K, Lautenbacher S (2011) The effects of oral contraceptives on detection and pain thresholds as well as headache intensity during menstrual cycle in migraine. Headache 51(1):92–104CrossRefPubMed

Loder EW, Buse DC, Golub JR (2005) Headache as a side effect of combination estrogen-progestin oral contraceptives: a systematic review. Am J Obstet Gynecol 193(3 Pt 1):636–649CrossRefPubMed

Archer DF, Jensen JT, Johnson JV, Borisute H, Grubb GS, Constantine GD (2006) Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception 74(6):439–445CrossRefPubMed

Macgregor EA (2007) Menstrual migraine: a clinical review. J Fam Plann Reprod Health Care 33(1):36–47CrossRefPubMed

Macgregor EA, Rosenberg JD, Kurth T (2011) Sex-related differences in epidemiological and clinic-based headache studies. Headache 51(6):843–859CrossRefPubMed

Chang CL, Donaghy M, Poulter N (1999) Migraine and stroke in young women: case–control study. The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. BMJ 318(7175):13–18CrossRefPubMedCentralPubMed

Bigal ME, Kurth T, Santanello N, Buse D, Golden W, Robbins M, Lipton RB (2010) Migraine and cardiovascular disease: a population-based study. Neurology 74(8):628–635CrossRefPubMedCentralPubMed

10.

Tzourio C, Tehindrazanarivelo A, Iglesias S, Alperovitch A, Chedru F, D’Anglejan-Chatillon J, Bouser MG (1995) Case–control study of migraine and risk of ischaemic stroke in young women. BMJ 310(6983):830–833CrossRefPubMedCentralPubMed

11.

Schurks M, Buring JE, Kurth T (2010) Migraine, migraine features, and cardiovascular disease. Headache 50(6):1031–1040CrossRefPubMedCentralPubMed

12.

Tzourio C, Iglesias S, Hubert JB, Visy JM, Alperovitch A, Tehindrazanarivelo A, Biousse V, Woimant F, Bousser MG (1993) Migraine and risk of ischaemic stroke: a case–control study. BMJ 307(6899):289–292CrossRefPubMedCentralPubMed

13.

Gillum LA, Mamidipudi SK, Johnston SC (2000) Ischemic stroke risk with oral contraceptives: A meta-analysis. JAMA 284(1):72–78CrossRefPubMed

14.

Sacco S, Ricci S, Degan D, Carolei A (2012) Migraine in women: the role of hormones and their impact on vascular diseases. J Headache Pain 13(3):177–189CrossRefPubMedCentralPubMed

15.

Lidegaard O, Lokkegaard E, Svendsen AL, Agger C (2009) Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 339:b2890CrossRefPubMedCentralPubMed

16.

Nappi RE, Merki-Feld GS, Terreno E, Pellegrinelli A, Viana M (2013) Hormonal contraception in women with migraine: is progestogen-only contraception a better choice? J Headache Pain 14:66CrossRefPubMedCentralPubMed

17.

Barkfeldt J, Virkkunen A, Dieben T (2001) The effects of two progestogen-only pills containing either desogestrel (75 microg/day) or levonorgestrel (30 microg/day) on lipid metabolism. Contraception 64(5):295–299CrossRefPubMed

18.

Kivela A, Ruuskanen M, Agren U, Dieben T (2001) The effects of two progrestogen-only pills containing either desogestrel (75 microgram/day) or levonorgestrel (30 microgram/day) on carbohydrate metabolism and adrenal and thyroid function. Eur J Contracept Reprod Health Care 6(2):71–77CrossRefPubMed

19.

Merki-Feld GS, Imthurn B, Langner R, Sandor PS, Gantenbein AR (2013) Headache frequency and intensity in female migraineurs using desogestrel-only contraception: a retrospective pilot diary study. Cephalalgia 33(5):340–346CrossRefPubMed

20.

Merki-Feld GS, Imthurn B, Seifert B, Merki LL, Agosti R, Gantenbein AR (2013) Desogestrel-only contraception reduces headache frequency and improves quality of life in female migraineurs. Eur J Contracept Reprod Health Care 18:394–400CrossRefPubMed

21.

IHS International Headache Society (2004) The International Classification of Headache Disorders: 2nd edition. Cephalalgia 24 Suppl 1:9–160

22.

Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN (2000) Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 88(1):41–52CrossRefPubMed

23.

Lipton RB, Stewart WF, Sawyer J, Edmeads JG (2001) Clinical utility of an instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) questionnaire. Headache 41(9):854–861CrossRefPubMed

24.

Silberstein S, Tfelt-Hansen P, Dodick DW, Limmroth V, Lipton RB, Pascual J, Wang SJ (2008) Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 28(5):484–495CrossRefPubMed

25.

Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Hertz S, Heyse JF, Iyengar S, Jadad AR, Jay GW, Jermano JA, Katz NP, Manning DC, Martin S, Max MB, McGrath P, McQuay HJ, Quessy S, Rappaport BA, Revicki DA, Rothman M, Stauffer JW, Svensson O, White RE, Witter J (2008) Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 9(2):105–121CrossRefPubMed

26.

Morotti M, Remorgida V, Venturini PL, Ferrero S (2014) Progestin-only contraception compared with extended combined oral contraceptive in women with migraine without aura: a retrospective pilot study. Eur J Obstet Gynecol Reprod Biol 183:178–182CrossRefPubMed

27.

Nappi RE, Sances G, Allais G, Terreno E, Benedetto C, Vaccaro V, Facchinetti F (2011) Effects of an estrogen-free, desogestrel-containing oral contraceptive in women with migraine with aura: a prospective diary-based pilot study. Contraception 83(3):223–228CrossRefPubMed

28.

Calhoun A, Ford S, Pruitt A (2012) The impact of extended-cycle vaginal ring contraception on migraine aura: a retrospective case series. Headache 52(8):1246–1253CrossRefPubMed

29.

De Leo V, Scolaro V, Musacchio MC, Di Sabatino A, Morgante G, Cianci A (2011) Combined oral contraceptives in women with menstrual migraine without aura. Fertil Steril 96(4):917–920CrossRefPubMed

30.

Sulak P, Willis S, Kuehl T, Coffee A, Clark J (2007) Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Headache 47(1):27–37CrossRefPubMed

31.

MacGregor EA, Guillebaud J (1998) Combined oral contraceptives, migraine and ischaemic stroke. Clinical and Scientific Committee of the Faculty of Family Planning and Reproductive Health Care and the Family Planning Association. Br J Fam Plann 24(2):55–60PubMed

32.

Lidegaard O, Nielsen LH, Skovlund CW, Lokkegaard E (2012) Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001–10. BMJ 344:e2990CrossRefPubMedCentralPubMed

33.

Merki-Feld GS, Breitschmid N, Seifert B, Kreft M (2014) A survey on Swiss women’s preferred menstrual/withdrawal bleeding pattern over different phases of reproductive life and with use of hormonal contraception. Eur J Contracept Reprod Health Care 19(4):266–275CrossRefPubMed

34.

Cutrer FM, Moskowitz MA (1996) Wolff Award 1996. The actions of valproate and neurosteroids in a model of trigeminal pain. Headache 36(10):579–585CrossRefPubMed

35.

Multon S, Pardutz A, Mosen J, Hua MT, Defays C, Honda S, Harada N, Bohotin C, Franzen R, Schoenen J (2005) Lack of estrogen increases pain in the trigeminal formalin model: a behavioural and immunocytochemical study of transgenic ArKO mice. Pain 114(1–2):257–265CrossRefPubMed

36.

Bolay H, Berman NE, Akcali D (2011) Sex-related differences in animal models of migraine headache. Headache 51(6):891–904CrossRefPubMed

37.

Joshi G, Pradhan S, Mittal B (2010) Role of the oestrogen receptor (ESR1 PvuII and ESR1 325 C- > G) and progesterone receptor (PROGINS) polymorphisms in genetic susceptibility to migraine in a North Indian population. Cephalalgia 30(3):311–320PubMed

38.

Liu A, Margaill I, Zhang S, Labombarda F, Coqueran B, Delespierre B, Marchand-Leroux C, O’Malley BW, Lydon JP, De Nicola AF, Sitruk-Ware R, Mattern C, Plotkine M, Schumacher M, Guennoun R (2012) Progesterone receptors: a key for neuroprotection in experimental stroke. Endocrinology 153(8):3747–3757CrossRefPubMedCentralPubMed

39.

Schumacher M, Mattern C, Ghoumari A, Oudinet JP, Liere P, Labombarda F, Sitruk-Ware R, De Nicola AF, Guennoun R (2013) Revisiting the roles of progesterone and allopregnanolone in the nervous system: Resurgence of the progesterone receptors. Prog Neurobiol 113:6–39CrossRefPubMed

40.

Kokate TG, Svensson BE, Rogawski MA (1994) Anticonvulsant activity of neurosteroids: correlation with gamma-aminobutyric acid-evoked chloride current potentiation. J Pharmacol Exp Ther 270(3):1223–1229PubMed

Title: Positive effects of the progestin desogestrel 75 μg on migraine frequency and use of acute medication are sustained over a treatment period of 180 days
Authors: Gabriele S Merki-Feld
Bruno Imthurn
Ronald Langner
Burkhardt Seifert
Andreas R Gantenbein
Publication date: 01-12-2015
Publisher: Springer Milan
Published in: The Journal of Headache and Pain / Issue 1/2015
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1186/s10194-015-0522-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Positive effects of the progestin desogestrel 75 μg on migraine frequency and use of acute medication are sustained over a treatment period of 180 days

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2015

Impact of headache disorders in Italy and the public-health and policy implications: a population-based study within the Eurolight Project

Alexithymic characteristics in pediatric patients with primary headache: a comparison between migraine and tension-type headache

Questioning on consistency of a Stagnation Scale in Medication Overuse Headache: one more added to a plea of emperor’s clothes?

Headache in epilepsy: prevalence and clinical features

High sensitivity C-reactive protein and cerebral white matter hyperintensities on magnetic resonance imaging in migraine patients

Look beyond Catechol-O-Methyltransferase genotype for cathecolamines derangement in migraine: the BioBIM rs4818 and rs4680 polymorphisms study